Vinge has advised Axcel in connection with the investment in XPartners Samhällsbyggnad (“XPartners”), a sustainability-focused technical consulting group, specialising in infrastructure, public and commercial buildings as well as environmental services.

Following Axcel’s investment, the XPartners’ group consists of nine business units employing approximately 400 people across 30 offices in Sweden, generating approximately SEK 600 million in revenue. XPartners is the first investment of Axcel Fund VII.

For more information about the transaction, please see the client’s press release.

Vinge’s team consisted primarily of Christina Kokko, Karl Klackenberg, Carl Fredrik Wachtmeister, Egil Svensson and Elsa Strandberg (M&A), Daniel Prawitz (Construction), Daniel Melander Björner and Tove Hallbäck (Employment), Mikael Ståhl, Seyran Sahin, Karl-Gustaw Tobola and Ida Redander (Financing), Alexandra Tamm (Real Estate), Tove Tullberg and Julia Löfqvist (Compliance), Lisa Hörnqvist (GDPR), Trine Osen Bergqvist, Victoria Fredén and Alva Chambert (ECR) and Emy Rydén (project assistant).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026